# Cisplatin

## Cisplatin 50mg-50mL

*藥物代碼*：ICIS

*給藥途徑*：I

*用法用量*：

Dosing: Adult
--Bladder cancer, advanced: I.V.: 50 to 70 mg/m2 every 3 to 4 weeks; heavily pretreated patients: 50 mg/m2 every 4 weeks 
--Ovarian cancer, metastatic: I.V.:Single agent: 100 mg/m2 every 4 weeks; Combination therapy: 75 to 100 mg/m2 every 4 weeks or (unlabeled dosing) 75 mg/m2 every 3 weeks
--Testicular cancer, metastatic: I.V.: 20 mg/m2/day for 5 days repeated every 3 weeks 
--Cervical cancer (unlabeled use): I.V.: 75 mg/m2 on day 1 every 3 weeks (in combination with fluorouracil and radiation) for 3 cycles (Morris, 1999) or 70 mg/m2 on day 1 every 3 weeks for 4 cycles (in combination with fluorouracil; cycles 1 and 2 given concurrently with radiation) or 50 mg/m2 on day 1 every 4 weeks (in combination with radiation and fluorouracil) for 2 cycles
--Endometrial carcinoma, recurrent, metastatic, or high-risk (unlabeled use): I.V.: 50 mg/m2 on day 1 every 3 weeks (in combination with doxorubicin ± paclitaxel) for 7 cycles or until disease progression or unacceptable toxicity
--Head and neck cancer (unlabeled use): I.V.:Locally-advanced disease: 100 mg/m2 every 3 weeks for 3 doses (with concurrent radiation) or 75 mg/m2 every 3 weeks (in combination with docetaxel and fluorouracil) for 4 cycles or until disease progression or unacceptable toxicity (if no disease progression after 4 cycles, chemotherapy was followed by radiation) or 100 mg/m2 every 3 weeks (in combination with docetaxel and fluorouracil) for 3 cycles or until disease progression or unacceptable toxicity (chemotherapy was followed by chemoradiation) 
--Metastatic disease: 100 mg/m2 every 3 weeks (in combination with fluorouracil and cetuximab) until disease progression or unacceptable toxicity or a maximum of 6 cycles 
--Malignant pleural mesothelioma (unlabeled use): I.V.: 75 mg/m2 on day 1 of each 21-day cycle (in combination with pemetrexed) or 100 mg/m2 on day 1 of a 28-day cycle (in combination with gemcitabine) or 80 mg/m2 on day 1 of a 21-day cycle (in combination with gemcitabine)
--Non-small cell lung cancer (NSCLC; unlabeled use): I.V.: Note: There are multiple cisplatin-containing regimens for the treatment of NSCLC. Listed below are several commonly used regimens:100 mg/m2 on day 1 every 4 weeks (in combination with etoposide) for 3 to 4 cycles; (Arriagada, 2007), or 100 mg/m2 on day 1 every 4 weeks (in combination with vinorelbine), or 100 mg/m2 on day 1 every 4 weeks (in combination with gemcitabine), or 80 mg/m2 on day 1 every 3 weeks (in combination with gemcitabine), or 75 mg/m2 on day 1 every 3 weeks (in combination with pemetrexed) for up to 6 cycles or until disease progression or unacceptable toxicity
--Ovarian cancer (unlabeled route): Intraperitoneal: 75 to 100 mg/m2 on day 2 of a 21-day treatment cycle (in combination with I.V. and intraperitoneal paclitaxel) for 6 cycles
--Small cell lung cancer (SCLC; unlabeled use): I.V.:Limited-stage disease: 60 mg/m2 on day 1 every 3 weeks for 4 cycles (in combination with etoposide and concurrent radiation)
--Extensive-stage disease: 80 mg/m2 on day 1 every 3 weeks (in combination with etoposide) for 4 cycles or a maximum of 8 cycles or 60 mg/m2 on day 1 every 4 weeks for 4 cycles (in combination with irinotecan)
--Testicular germ cell tumor, malignant (unlabeled use): I.V.: 25 mg/m2 on days 2 to 5 every 3 weeks (in combination with paclitaxel and ifosfamide) for 4 cycles or 20 mg/m2 on days 1 to 5 every 3 weeks (in combination with bleomycin and etoposide) for 4 cycles or 20 mg/m2 on days 1 to 5 every 3 weeks (in combination with etoposide and ifosfamide) for 4 cycles

